Target intelligence / Profile preview

Enzymes involved in neurotransmitter synthesis

Molecular classification
Enzyme
01

Overview

Enzymes involved in neurotransmitter synthesis represent a diverse group of proteins that catalyze the chemical conversion of precursors into active signaling molecules within the central and peripheral nervous systems. This functional class includes several key rate-limiting enzymes such as tyrosine hydroxylase (TH) for catecholamine production and tryptophan hydroxylase (TPH) for serotonin synthesis, as well as aromatic L-amino acid decarboxylase (AADC) and choline acetyltransferase (ChAT) [PMID: 21303100, PMID: 12821654]. By regulating the availability of neurotransmitters like dopamine, serotonin, and acetylcholine, these enzymes are vital for mood regulation, movement control, and cognitive functions [StatPearls: Neuroanatomy, Neurotransmitters]. Pathological changes in the activity or expression of these enzymes are linked to various conditions, including Parkinson's disease, depression, and schizophrenia [PMID: 21303100]. Therapeutic interventions frequently target these pathways using enzyme inhibitors like carbidopa or metyrosine to modulate levels, or by providing exogenous precursors like levodopa to restore chemical balance in neurotransmitter-deficient states [NIH: PubChem, StatPearls: Carbidopa].

Other names
Neurotransmitter biosynthetic enzymesNeurotransmitter synthetic enzymesBiogenic amine synthesis enzymesNeurotransmitter-associated enzymes
02

Mechanism of action

Inhibition of rate-limiting biosynthetic enzymes to reduce neurotransmitter production or administration of metabolic precursors to bypass synthetic bottlenecks and enhance neurotransmitter levels.

03

Biological functions

Neurotransmitter synthesisMetabolic processSynaptic transmissionSignal transductionHomeostatic plasticity
04

Disease associations

Parkinson's diseaseMajor depressive disorderSchizophreniaHypertensionAnxiety disorderBipolar disorderAromatic L-amino acid decarboxylase deficiency
05

Safety considerations

Neurotransmitter depletion syndromeMovement disorders (e.g., dyskinesia)Psychiatric disturbances (e.g., hallucinations, anxiety)Orthostatic hypotensionRisk of serotonin syndrome when combined with other serotonergic agents
06

Interacting drugs

Levodopa

6 more in the full profile.

07

Biomarkers

Cerebrospinal fluid (CSF) monoamine metabolite levels (e.g., HVA, 5-HIAA, VMA)Urinary catecholaminesPlasma 3-methoxy-4-hydroxyphenylglycol (MHPG)Enzyme activity assays in serum or tissuePET imaging of [18F]fluorodopa uptake

Beyond the preview

Go deeper on Enzymes involved in neurotransmitter synthesis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enzymes involved in neurotransmitter synthesis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call